{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:30:28Z","timestamp":1790566228200,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.thromres.2023.02.001","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:30:04Z","timestamp":1676428204000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer"],"prefix":"10.1016","volume":"224","author":[{"given":"Amol D.","family":"Dhamane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrushti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Noxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bruette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.thromres.2023.02.001_bb0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","article-title":"Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study","volume":"162","author":"Heit","year":"2002","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2023.02.001_bb0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2023.02.001_bb0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2023.02.001_bb0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.thromres.2023.02.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med."},{"issue":"15","key":"10.1016\/j.thromres.2023.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"Elting","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.thromres.2023.02.001_bb0035","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2023.02.001_bb0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997\u20132006","volume":"103","author":"Cronin-Fenton","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.thromres.2023.02.001_bb0045","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<968::AID-CNCR5>3.0.CO;2-8","article-title":"Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials","volume":"78","author":"Holm","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.thromres.2023.02.001_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamasurg.2013.3172","article-title":"Venous thromboembolism after major cancer surgery: temporal trends and patterns of care","volume":"149","author":"Trinh","year":"2014","journal-title":"JAMA Surg."},{"issue":"11","key":"10.1016\/j.thromres.2023.02.001_bb0055","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/13696998.2019.1620752","article-title":"Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants","volume":"22","author":"Streiff","year":"2019","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.thromres.2023.02.001_bb0060","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"J. Oncol. Pract."},{"issue":"13","key":"10.1016\/j.thromres.2023.02.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.thromres.2023.02.001_bb0070","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.thromres.2023.02.001_bb0075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2023.02.001_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2023.02.001_bb0085","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"5","key":"10.1016\/j.thromres.2023.02.001_bb0090","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2023.02.001_bb0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2023.02.001_bb0100","author":"Institute"},{"issue":"25","key":"10.1016\/j.thromres.2023.02.001_bb0105","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.02.001_bb0110","first-page":"CD011088","article-title":"Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism","volume":"12","author":"Robertson","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.thromres.2023.02.001_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/ehm.11.86","article-title":"Treating venous thromboembolism in patients with cancer","volume":"5","author":"Piatek","year":"2012","journal-title":"Expert. Rev. Hematol."},{"issue":"23 Suppl 1","key":"10.1016\/j.thromres.2023.02.001_bb0120","first-page":"I17","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.thromres.2023.02.001_bb0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2023.02.001_bb0130","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1007\/s12325-021-01918-0","article-title":"Effectiveness and safety of apixaban versus warfarin among older patients with venous thromboembolism with different demographics and socioeconomic status","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.thromres.2023.02.001_bb0135","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1160\/TH17-03-0210","article-title":"Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism","volume":"117","author":"Coleman","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2023.02.001_bb0140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.amjmed.2018.02.015","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism","volume":"131","author":"Coleman","year":"2018","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2023.02.001_bb0145","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1080\/03007995.2019.1653067","article-title":"Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population","volume":"35","author":"Hlavacek","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.thromres.2023.02.001_bb0150","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1007\/s12325-022-02200-7","article-title":"Comparative analysis of all-cause health care resource utilization and costs among venous thrombosis patients without cancer prescribed apixaban or VKAs in France","volume":"39","author":"Mokgokong","year":"2022","journal-title":"Adv. Ther."},{"issue":"11","key":"10.1016\/j.thromres.2023.02.001_bb0155","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2022.1920","article-title":"Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism","volume":"327","author":"Pawar","year":"2022","journal-title":"JAMA"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:59Z","timestamp":1758736199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":31,"alternative-id":["S0049384823000415"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.02.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}